Column Group III, LP sells TNYA shares in Feb 2026

COLUMN GROUP III, LP reported sales of common stock in TNYA-related transactions identified in a Form 144 notice.

Rhea-AI Filing Summary

COLUMN GROUP III, LP reported sales of common stock in TNYA-related transactions identified in a Form 144 notice. The filing lists multiple sales dated 02/10/2026 through 02/24/2026, including 1,904,115 shares on 02/11/2026 for $1,297,002.29 and 309,228 shares on 02/24/2026 for $190,267.99.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did COLUMN GROUP III, LP report in the TNYA Form 144?

They reported multiple share sales of TNYA common stock. The filing lists transactions from 02/10/2026 to 02/24/2026, with per‑trade shares and gross proceeds shown for each date.

How many shares did COLUMN GROUP III, LP sell on 02/11/2026?

They sold 1,905,115 shares on 02/11/2026 for $1,297,002.29. This line appears in the section labeled "Securities Sold During The Past 3 Months" with per‑trade proceeds.

What are examples of other sale dates and amounts in the filing?

Examples include 161,422 shares on 02/10/2026 for $131,736.49 and 309,228 shares on 02/24/2026 for $190,267.99 as listed in the sales table.

Does the Form 144 excerpt state the method or proceeds recipient?

The excerpt lists share counts and gross proceeds per trade but does not specify sales methods or who received proceeds. The table shows dates, shares sold, and dollar amounts only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 05:05 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001668159
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tenaya Therapeutics, Inc.
SEC File Number	001-40656
Address of Issuer	171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	415-865-2066
Name of Person for Whose Account the Securities are To Be Sold	COLUMN GROUP III, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	939273	565442.00	213744535	02/25/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/20/2018	Series A financing	Tenaya Therapeutics			277733	12/20/2018	Cash
Common	08/30/2019	Series B financing	Tenaya Therapeutics			157553	08/30/2019	Cash
Common	03/30/2020	Series B financing	Tenaya Therapeutics			157553	03/30/2020	Cash
Common	08/25/2020	Series B financing	Tenaya Therapeutics			157553	08/25/2020	Cash
Common	12/17/2020	Series B financing	Tenaya Therapeutics			188881	12/17/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	161422	131736.49
COLUMN GROUP III, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/11/2026	1905115	1297002.29
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/20/2026	245965	151243.88
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/23/2026	143709	85823.01
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/24/2026	309228	190267.99

144: Remarks and Signature

Remarks
Date of Notice	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Evangelista
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)